Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alimera Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alimera Sciences's position in the market.
Alimera Sciences, Inc. (NASDAQ: ALIM) will showcase a corporate overview by CEO Rick Eiswirth at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on September 15, 2020, at 3:30 PM ET. A live and archived presentation will be accessible on Alimera's website. Eiswirth is also available for one-on-one virtual meetings from September 14-16, 2020. Alimera specializes in developing ophthalmic pharmaceuticals, focusing on treating retinal diseases, which are prevalent in aging populations.
Alimera Sciences (Nasdaq: ALIM) has commenced its NEW DAY clinical trial, enrolling its first patient to evaluate ILUVIEN as a baseline therapy for diabetic macular edema (DME). The randomized, controlled study will involve approximately 300 treatment-naïve patients across 42 U.S. sites. The primary aim is to compare the mean number of supplemental aflibercept injections needed between ILUVIEN and standard treatment. Previous studies have indicated ILUVIEN's potential for prolonged vision maintenance with fewer injections, marking a significant step in DME treatment strategies.
Alimera Sciences (NASDAQ: ALIM) announced that its European subsidiary received pricing and reimbursement approval for ILUVIEN® in the Netherlands, effective September 1, 2020. This approval, obtained through distribution partner Horus Pharma, covers diabetic macular edema and non-infectious posterior uveitis indications. The CEO highlighted the positive trajectory of ILUVIEN's launch in France and anticipates expanding into the Benelux region.
Alimera Sciences (NASDAQ: ALIM) announced a distribution agreement with Nordic Prime ApS for the ILUVIEN 190 micrograms intravitreal implant in Denmark, Finland, Norway, and Sweden. The agreement enables Nordic Prime to handle hospital tendering and distribution for ILUVIEN, which treats vision impairment associated with chronic diabetic macular edema and non-infectious uveitis. CEO Rick Eiswirth highlighted this expansion aims to increase global market share, noting over 100,000 patients in the region suffer from these conditions.
Alimera Sciences (Nasdaq: ALIM) will report its second quarter 2020 financial results on July 29, 2020, after market close. Management will host a conference call at 9:00 AM ET on July 30, 2020, to discuss the results and corporate developments, followed by a Q&A session. Pre-registration is required for the call, with dial-in options available for those who cannot register online. A replay will be accessible for a limited time after the call. Alimera specializes in ophthalmic pharmaceuticals addressing retinal diseases.
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020. The corporate presentation is scheduled for June 9 at 3:55 pm ET, followed by a live Q&A session with investors. A live webcast will be available here. Investors can also request one-on-one meetings with Eiswirth via email. Alimera specializes in developing treatments for retinal diseases, addressing significant unmet needs in ophthalmology.
Summary not available.